Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/51865| Title: | Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis |
| Authors: | Attapon Cheepsattayakorn Ruangrong Cheepsattayakorn |
| Authors: | Attapon Cheepsattayakorn Ruangrong Cheepsattayakorn |
| Keywords: | Medicine;Pharmacology, Toxicology and Pharmaceutics |
| Issue Date: | 23-Jul-2012 |
| Abstract: | A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide. © 2012 Bentham Science Publishers. |
| URI: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84863919123&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/51865 |
| ISSN: | 1574891X |
| Appears in Collections: | CMUL: Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.